Bangladesh Pharmaceutical Industry Analysis
Growth, API Dependency, and the Post-LDC TRIPS Transition
BDPolicyLab · 2026-06-15
On November 24, 2026, Bangladesh loses the WTO TRIPS pharmaceutical waiver that lets local firms formulate patented molecules without licences. The waiver runs to end-2033, but only for countries that stay LDCs: graduation forfeits it. The exposed slice is narrow but high-value, the roughly one-fifth of the domestic pipeline that is patented (PRI, 2020), and the binding move is not the API Park or new R&D but a graduating-LDC extension request lodged at the WTO before graduation, citing the Maldives public-health precedent. Everything else is a multi-year build the extension buys time to finish.
Key findings
- Pharmaceutical exports reached $213.16 million in FY25 across 166 countries, more than double FY18. Export Promotion Bureau data put pharmaceutical export earnings at $213.16 million in FY25, up 3.74% on FY24 and more than double the $103.46 million of FY18, with destinations rising from about 140 countries to 166. The sector supplies roughly 98% of domestic demand (World Bank, 2024) from a market of about $3.5 billion (DCCI, 2023). (Source: EPB / The Daily Star, FY25; World Bank 2024; DCCI Annual Report 2023.)
- Graduation, not the end-2033 sunset, is what ends the waiver: the binding date is November 24, 2026. The WTO LDC pharmaceutical waiver runs to end-2033 for countries that remain LDCs; Bangladesh forfeits it at graduation on November 24, 2026. About 20% of drugs made in Bangladesh are patented rather than generic (PRI, 2020); after graduation those molecules need patent clearance, licensing, or compulsory licensing. The TRIPS Council granted Maldives a public-health extension, a precedent for a graduating-LDC request. (Source: WTO TRIPS Council; PRI WP25 2020; Bangladesh Enterprise Institute, Navigating New Waters.)
- API import dependence above 85% is the cost cliff sitting behind the patent cliff. Bangladesh imports more than 85% of Active Pharmaceutical Ingredients, mainly from China and India, at an annual bill of about $1.3 to $1.5 billion (The Daily Star, 2025). The 2020-2021 supply shock showed how fast that exposure becomes production risk. The FY2026-27 budget grants full duty exemption on 51 new API raw materials (NBR, 2026), but the Munshiganj API Park has slipped from its end-2011 deadline across a decade of budget cycles (CPD). (Source: The Daily Star 2025; NBR Budget Speech FY2026-27; CPD Interim Reviews.)
- WHO prequalification, not price, is the ceiling on Bangladesh's highest-value export markets. Prequalified products open UN and donor procurement (UNICEF, Global Fund, USAID programmes) and ease regulated-market dossier acceptance. Bangladesh holds only a small number of prequalified products, with Beximco's lamivudine tablet among the first, so the price advantage that reached 166 countries does not yet convert into the regulated tiers that survive graduation. (Source: WHO Prequalification Programme.)
Bangladesh's pharmaceutical industry is a manufacturing success built on a legal
exemption. EPB data put exports at $213.16 million in FY25 across 166 countries,
more than double the $103.46 million of FY18, on a sector that supplies about 98%
of a roughly $3.5 billion domestic market. That edge rests on the WTO TRIPS LDC
waiver, which lets local firms formulate patented molecules without licences. On
November 24, 2026, graduation removes it. The single highest-value policy move is
to secure a post-graduation extension; everything else (API capacity, R&D, WHO
prequalification) is a multi-year build that the extension buys time to complete.
What graduation changes
The LDC pharmaceutical waiver runs to end-2033, but only for countries that remain
LDCs. The trap is that graduation, not the calendar, ends it: Bangladesh forfeits
the waiver on November 24, 2026, seven years before the nominal sunset. From that
date the patented slice of the pipeline, about 20% of drugs made here versus 80%
generic (PRI, 2020), can no longer be freely copied; new launches need patent
clearance, licensing, or compulsory licensing. CPD's health-budget analysis states
the consequence plainly: unless Bangladesh secures an extension of the transition
period after it graduates in 2026, the waiver will be withdrawn (CPD, Health Budget
of Bangladesh). The Dhaka Chamber flagged the same cliff in its 2022 annual report,
naming the post-2026 risk to the sector directly (DCCI Annual Report 2022).
There is a usable precedent. The TRIPS Council granted Maldives an extension on
public-health grounds, which Bangladesh can cite to make a "duly motivated request"
for graduating LDCs (Bangladesh Enterprise Institute, Navigating New Waters: LDC
Graduation and Exports). Bangladesh has filed for a 3-year graduation deferral and
is separately lobbying to extend the pharmaceutical waiver to 2029.
API dependency: the cost cliff behind the patent cliff
Even with the waiver extended, the sector imports more than 85% of its Active
Pharmaceutical Ingredients, mainly from China and India, at an annual bill of about
$1.3 to $1.5 billion (The Daily Star, 2025). The 2020-2021 supply shock showed how
fast that exposure converts to production risk. Two levers are now in play. The
FY2026-27 budget grants full duty exemption on 51 new API raw materials to push
local production (NBR Budget Speech FY2026-27). Against that, the flagship API Park
in Munshiganj has a long record of slippage: CPD's macroeconomic reviews repeatedly
noted that establishment of the API Park was "inordinately delayed" against its
original end-2011 timeline (CPD, Bangladesh Economy Interim Reviews). Treating
"behind schedule" as a dated fact, not an assertion: the park has missed its
deadline by more than a decade of budget cycles. Post-graduation, USD-denominated
API imports compound the risk whenever the taka depreciates and a licensing premium
is layered on top.
Quality access is the export ceiling
WHO prequalification, not price, caps Bangladesh's reach into the highest-value
markets. PQ products open UN and donor procurement (UNICEF, Global Fund, USAID
programmes) and ease regulated-market dossier acceptance. Today Bangladesh holds
only a small number of prequalified products, with Beximco's lamivudine tablet
among the first to clear the WHO programme. The price advantage that drove exports
to 166 countries is exactly what erodes if patent and quality barriers rise
together after graduation: the same labour-cost edge competes against India and
China in the shrinking unregulated tier.
Recommendations
- **Ministry of Commerce and the WTO mission file the TRIPS extension request now,
citing the Maldives precedent.** The ask is a graduating-LDC pharmaceutical
waiver to 2029, lodged before the November 24, 2026 graduation date. Owner:
Commerce Secretary plus the Geneva mission. Expected effect: patent-free
formulation of the patented ~20% of the pipeline is preserved while capability
builds. Success signal: a TRIPS Council decision text granting graduating LDCs an
extension before graduation day.
- Cabinet sets a dated API Park delivery milestone and publishes it. The park
has slipped from its end-2011 deadline for over a decade. Owner: Ministry of
Industries. Expected effect: open-ended "underway" language is replaced by a
public count of operational units and a target year. Success signal: a verified
operational-unit count reported each budget cycle against the published target.
- DGDA runs a WHO prequalification push tied to donor procurement. Co-finance
bioequivalence studies and dossier preparation for the leading exporters. Owner:
DGDA with BAPI. Expected effect: prequalified products multiply from today's
small base, converting the 166-country reach into access to UNICEF and Global
Fund tenders that survive graduation. Success signal: a year-on-year rise in the
count of Bangladesh products listed in the WHO PQ database.
- **NBR keeps API inputs zero-rated and holds the line on the 2.4% VAT on local
medicine trade.** The FY2026-27 budget already exempts duty on 51 API raw
materials; CPD has urged zeroing import taxes on API and warns against the 2.4%
VAT on locally traded medicines in view of graduation (CPD, Health Budget of
Bangladesh). Owner: NBR. Expected effect: the input cost base is held down while
the patent and API transitions land. Success signal: no net increase in the
landed tax on API or finished medicine through the transition window.
What would change this view
If the WTO declines a graduating-LDC pharmaceutical extension despite the Maldives
precedent, the timeline collapses and the priority shifts from buying time to
emergency licensing and import sourcing for the patented ~20%. If the API Park
posts verified operational units against a published milestone, the API-dependency
risk downgrades from structural to managed. And if export earnings continue past
the $213.16 million FY25 mark into regulated markets via WHO PQ, the quality
ceiling, not the patent cliff, becomes the binding constraint.
*Sources: EPB (Export Promotion Bureau); DGDA (Directorate General of Drug
Administration); World Bank (2024); DCCI Annual Report 2022 and 2023; PRI (Policy
Research Institute), WP25 2020; WHO Prequalification Programme; WTO TRIPS Council;
UN Committee for Development Policy; CPD (Health Budget of Bangladesh, Bangladesh
Economy Interim Reviews); NBR Budget Speech FY2026-27; Bangladesh Enterprise
Institute, Navigating New Waters; The Daily Star.*
Data and methodology
Export earnings and destination counts from EPB monthly statements (FY25), cross-checked against The Daily Star reporting of EPB data. Domestic market size from DCCI Annual Report 2023; domestic-demand share from the World Bank (2024). Generic-versus-patented split from PRI WP25 (2020). API import dependence and the import bill from The Daily Star (2025) and DGDA. FY2026-27 fiscal measures from the NBR Budget Speech. WHO prequalification status from the WHO Prequalification public database. TRIPS waiver timeline from WTO documents and the UN CDP graduation decision. Analysis by BDPolicyLab.